Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q1 2022 · 10-Q
Revenue$164.90M$164.90M−4.7% vs Q1 2021 Net Income-$20.50M-$20.50MN/M vs Q1 2021 EPS Diluted-$0.26-$0.26N/M vs Q1 2021 Operating Income-$25,600,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Free Cash Flowderived-$52,800,000N/M Margins · derivedOperating margin-15.5%+11.5 pt vs Q1 2021
Net margin-12.4%+10.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 6, 2022 · 36 d after period end